Cargando…
Application of VIP Care in Patients with Advanced Tumors in the Western Region of China
OBJECTIVE: The objective of this study is to explore the application of a very important person (VIP) intervention mode in patients with advanced tumors in the western region of China. METHODS: One hundred and sixty-three patients were randomly divided into a control and experimental groups. The con...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9453040/ https://www.ncbi.nlm.nih.gov/pubmed/36093398 http://dx.doi.org/10.1155/2022/7834620 |
_version_ | 1784785055137136640 |
---|---|
author | Zheng, Xiaoqin Peng, Yanqiong Liu, Chonghua Li, Fei Zhang, Haiying Liao, Jia Wu, Guirong Zeng, Xiaomei Xie, Nan |
author_facet | Zheng, Xiaoqin Peng, Yanqiong Liu, Chonghua Li, Fei Zhang, Haiying Liao, Jia Wu, Guirong Zeng, Xiaomei Xie, Nan |
author_sort | Zheng, Xiaoqin |
collection | PubMed |
description | OBJECTIVE: The objective of this study is to explore the application of a very important person (VIP) intervention mode in patients with advanced tumors in the western region of China. METHODS: One hundred and sixty-three patients were randomly divided into a control and experimental groups. The control group received routine care, and the experimental group received VIP future care. The willingness to end-of-life treatment, decision-making certainty, and quality of life were compared between the two groups before intervention (T0), after intervention (T1), and 1 month after intervention (T2). RESULTS: There were no significant differences in the basic data of the two groups. Unlike the control group, the experimental group preferred palliative care at the end of T1 (P < 0.05), and the acceptance rate of cardiopulmonary resuscitation and mechanical treatment decreased significantly. After the VIP intervention, the patient was transferred to the intensive care unit (ICU) (P < 0.05). After 1 month of intervention (T2), the results showed that the overall quality of life, physical discomfort, negative emotions, care and support, survival predicament, and lifetime value of the patients were significantly higher than those before the intervention (all P < 0.05). Decision certainty results showed that the differences between the T0, T1, and T2 time points and the interaction between groups and time were statistically significant, and the interaction was more significant at T2 (P < 0.05). CONCLUSION: VIP future care can change patients' wishes for end-of-life care, improve patients' and quality of life, and increase patient decision-making certainty. |
format | Online Article Text |
id | pubmed-9453040 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Hindawi |
record_format | MEDLINE/PubMed |
spelling | pubmed-94530402022-09-09 Application of VIP Care in Patients with Advanced Tumors in the Western Region of China Zheng, Xiaoqin Peng, Yanqiong Liu, Chonghua Li, Fei Zhang, Haiying Liao, Jia Wu, Guirong Zeng, Xiaomei Xie, Nan Biomed Res Int Research Article OBJECTIVE: The objective of this study is to explore the application of a very important person (VIP) intervention mode in patients with advanced tumors in the western region of China. METHODS: One hundred and sixty-three patients were randomly divided into a control and experimental groups. The control group received routine care, and the experimental group received VIP future care. The willingness to end-of-life treatment, decision-making certainty, and quality of life were compared between the two groups before intervention (T0), after intervention (T1), and 1 month after intervention (T2). RESULTS: There were no significant differences in the basic data of the two groups. Unlike the control group, the experimental group preferred palliative care at the end of T1 (P < 0.05), and the acceptance rate of cardiopulmonary resuscitation and mechanical treatment decreased significantly. After the VIP intervention, the patient was transferred to the intensive care unit (ICU) (P < 0.05). After 1 month of intervention (T2), the results showed that the overall quality of life, physical discomfort, negative emotions, care and support, survival predicament, and lifetime value of the patients were significantly higher than those before the intervention (all P < 0.05). Decision certainty results showed that the differences between the T0, T1, and T2 time points and the interaction between groups and time were statistically significant, and the interaction was more significant at T2 (P < 0.05). CONCLUSION: VIP future care can change patients' wishes for end-of-life care, improve patients' and quality of life, and increase patient decision-making certainty. Hindawi 2022-08-31 /pmc/articles/PMC9453040/ /pubmed/36093398 http://dx.doi.org/10.1155/2022/7834620 Text en Copyright © 2022 Xiaoqin Zheng et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Zheng, Xiaoqin Peng, Yanqiong Liu, Chonghua Li, Fei Zhang, Haiying Liao, Jia Wu, Guirong Zeng, Xiaomei Xie, Nan Application of VIP Care in Patients with Advanced Tumors in the Western Region of China |
title | Application of VIP Care in Patients with Advanced Tumors in the Western Region of China |
title_full | Application of VIP Care in Patients with Advanced Tumors in the Western Region of China |
title_fullStr | Application of VIP Care in Patients with Advanced Tumors in the Western Region of China |
title_full_unstemmed | Application of VIP Care in Patients with Advanced Tumors in the Western Region of China |
title_short | Application of VIP Care in Patients with Advanced Tumors in the Western Region of China |
title_sort | application of vip care in patients with advanced tumors in the western region of china |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9453040/ https://www.ncbi.nlm.nih.gov/pubmed/36093398 http://dx.doi.org/10.1155/2022/7834620 |
work_keys_str_mv | AT zhengxiaoqin applicationofvipcareinpatientswithadvancedtumorsinthewesternregionofchina AT pengyanqiong applicationofvipcareinpatientswithadvancedtumorsinthewesternregionofchina AT liuchonghua applicationofvipcareinpatientswithadvancedtumorsinthewesternregionofchina AT lifei applicationofvipcareinpatientswithadvancedtumorsinthewesternregionofchina AT zhanghaiying applicationofvipcareinpatientswithadvancedtumorsinthewesternregionofchina AT liaojia applicationofvipcareinpatientswithadvancedtumorsinthewesternregionofchina AT wuguirong applicationofvipcareinpatientswithadvancedtumorsinthewesternregionofchina AT zengxiaomei applicationofvipcareinpatientswithadvancedtumorsinthewesternregionofchina AT xienan applicationofvipcareinpatientswithadvancedtumorsinthewesternregionofchina |